92.29
1.85%
+1.68
Blueprint Medicines Corp stock is currently priced at $92.29, with a 24-hour trading volume of 783.55K.
It has seen a +1.85% increased in the last 24 hours and a +6.03% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $89.93 pivot point. If it approaches the $93.34 resistance level, significant changes may occur.
Previous Close:
$90.61
Open:
$90.48
24h Volume:
783.55K
Market Cap:
$5.65B
Revenue:
$249.38M
Net Income/Loss:
$-506.98M
P/E Ratio:
-10.04
EPS:
-9.19
Net Cash Flow:
$-452.91M
1W Performance:
+7.20%
1M Performance:
+6.03%
6M Performance:
+109.04%
1Y Performance:
+88.15%
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
38 Sidney Street, Cambridge, MA
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-21-23 | Reiterated | Needham | Buy |
Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-14-22 | Initiated | Needham | Buy |
Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-14-22 | Initiated | Berenberg | Buy |
Jul-08-22 | Initiated | Oppenheimer | Outperform |
Jun-27-22 | Initiated | Wells Fargo | Underweight |
Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
Mar-01-22 | Initiated | Citigroup | Neutral |
Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jan-25-22 | Upgrade | Stifel | Hold → Buy |
Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Sep-30-21 | Resumed | Stifel | Hold |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
Mar-31-21 | Initiated | Credit Suisse | Neutral |
Dec-03-20 | Initiated | Stifel | Hold |
Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
May-05-20 | Initiated | Barclays | Equal Weight |
Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
Oct-03-19 | Initiated | H.C. Wainwright | Buy |
Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-29-19 | Initiated | Piper Jaffray | Neutral |
Aug-15-19 | Resumed | Raymond James | Mkt Perform |
Jul-18-19 | Initiated | Deutsche Bank | Buy |
May-23-19 | Resumed | Goldman | Buy |
Apr-03-19 | Initiated | Morgan Stanley | Overweight |
Sep-25-18 | Initiated | Leerink Partners | Outperform |
Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Decoding 6 Analyst Evaluations For Blueprint Medicines
Benzinga
CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
Zacks Investment Research
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
Zacks Investment Research
Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
Zacks Investment Research
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
Zacks Investment Research
Blueprint Medicines Corp Stock (BPMC) Financials Data
Blueprint Medicines Corp (BPMC) Revenue 2024
BPMC reported a revenue (TTM) of $249.38 million for the quarter ending December 31, 2023, a +22.22% rise year-over-year.
Blueprint Medicines Corp (BPMC) Net Income 2024
BPMC net income (TTM) was -$506.98 million for the quarter ending December 31, 2023, a +9.06% increase year-over-year.
Blueprint Medicines Corp (BPMC) Cash Flow 2024
BPMC recorded a free cash flow (TTM) of -$452.91 million for the quarter ending December 31, 2023, a +11.40% increase year-over-year.
Blueprint Medicines Corp (BPMC) Earnings per Share 2024
BPMC earnings per share (TTM) was -$8.36 for the quarter ending December 31, 2023, a +10.59% growth year-over-year.
Blueprint Medicines Corp Stock (BPMC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Landsittel Michael | CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Option Exercise |
36.05 |
5,000 |
180,250 |
52,286 |
Landsittel Michael | CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Sale |
95.00 |
5,000 |
475,000 |
47,286 |
Albers Jeffrey W. | Director |
Mar 20 '24 |
Option Exercise |
7.11 |
25,073 |
178,287 |
201,123 |
Albers Jeffrey W. | Director |
Mar 20 '24 |
Sale |
87.28 |
25,073 |
2,188,264 |
176,050 |
Landsittel Michael | CHIEF FINANCIAL OFFICER |
Mar 15 '24 |
Option Exercise |
36.05 |
5,000 |
180,250 |
61,020 |
Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER |
Mar 15 '24 |
Option Exercise |
15.01 |
1,600 |
24,016 |
18,662 |
Landsittel Michael | CHIEF FINANCIAL OFFICER |
Mar 15 '24 |
Sale |
87.78 |
13,734 |
1,205,606 |
47,286 |
Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER |
Mar 15 '24 |
Sale |
87.76 |
4,549 |
399,213 |
14,913 |
Lee Philina | CHIEF COMMERCIAL OFFICER |
Mar 13 '24 |
Option Exercise |
13.15 |
1,747 |
22,975 |
42,752 |
Lee Philina | CHIEF COMMERCIAL OFFICER |
Mar 13 '24 |
Sale |
90.40 |
8,023 |
725,277 |
34,729 |
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):